Spire Healthcare Group (LON:SPI) Shares Down 18.1% on Analyst Downgrade

Spire Healthcare Group plc (LON:SPI)’s stock price was down 18.1% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.95 ($2.38). Approximately 8,024,729 shares were traded during mid-day trading, an increase of 1,005% from the average daily volume of 726,218 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a quick ratio of 0.74, a current ratio of 0.70 and a debt-to-equity ratio of 62.25. The business’s 50 day moving average price is GBX 227.28 and its 200-day moving average price is GBX 229.74. The company has a market cap of £711.58 million, a PE ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last announced its quarterly earnings data on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share (EPS) for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. As a group, analysts forecast that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.